Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Apr 11, 2014 2:55pm

117 Views

Post# 22441309

RE:FDA's BREAKTHROUGH DESIGNATION - COULD RVX-208 QUALIFY?

Jkj. This is very interesting.

This is what I was inquiring about a few weeks back on these posts. Perhaps, given the rvx-208 MACE results RVX could fit within this program? Why not, if lives could be saved or extended in a painless and compfortable way.

Cheers
Toinv :-)

Bullboard Posts

How one company is disrupting PoC testing